Skip to main content
Caplight Logo









Olatec Therapeutics

Olatec Therapeutics

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.olatec.com/

Last Round

Series B

Nov 9, 2025

Total Funding Raised

$40M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Olatec Therapeutics is a biopharmaceutical company that develops oral small-molecule therapeutics targeting the NLRP3 inflammasome and Interleukin-1 pathways to treat inflammatory and immune-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

NLRP3 inflammasome inhibitordapansutrilesmall-molecule therapeuticsclinical-stage biotechanti-inflammatory druginnate immune responsedrug developmentclinical trialsbiopharmaOLT1177immuno-endocrinologyoral therapychronic inflammationbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Olatec Therapeutics Comparables

Compare Olatec Therapeutics with similar companies based on industry and business-model similarity.

Olatec Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NodThera
87%
IFM Therapeutics
86%
Halia Therapeutics
86%

Olatec Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 9, 2025
GrantFeb 20, 2024
GrantMar 10, 2023
Series AFeb 23, 2023

Key People

Founding team and executive leadership

Damaris Skouras

Founder CEO

Founding Team

Olatec Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors grew 156% MoM.

  • Oct 2, 2025

    Andy Cunningham joins the Board of Directors.

Olatec Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Olatec Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Olatec Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range14
Year Founded2003
Last FundingNov 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?